Indication: VONVENDI [von Willebrand factor (recombinant)] is used in adults (age 18 years and older) diagnosed with von Willebrand disease to: treat and control bleeding episodes and prevent excessive bleeding during and after surgery

Menu

References

  1. Canadian Hemophilia Society. All About von Willebrand Disease...for people with von Willebrand disease and their families. 2011. http://www.hemophilia.ca/files/All%20About%20VWD%202011%20-%20FINAL.pdf. Accessed June 1, 2017.
  2. Facts about von Willebrand disease. Centers for Disease Control and Prevention website. https://www.cdc.gov/ncbddd/vWd/facts.html. Updated November 17, 2016. Accessed June 1, 2017.
  3. National Hemophilia Foundation. Strategic Summit on von Willebrand Disease. 2015. https://www.hemophilia.org/sites/default/files/article/documents/NHF-Strategic-Summit-Report-on-von-Willebrand-disease_1.pdf. Accessed June 1, 2017.
  4. VONVENDI Prescribing Information.
  5. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25:206-216.
  6. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
  7. Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046.